bioAffinity Technologies, Inc. (BIAF): EBITDA
-$10.07M
Year ended 2025-12-31
-$11.97M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$10.07M | n/m | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | -$8.35M | n/m | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | -$7.72M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$4.00M | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$2.20M | n/a | 2023-03-31, From 2021-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | -$10.07M | n/m |
| Absci Corp (ABSI) | 2025-12-31 | -$108.58M | n/m |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | -$9.73M | n/m |
| OmniAb, Inc. (OABI) | 2025-12-31 | -$47.22M | n/m |
| iSpecimen Inc. (ISPC) | 2025-12-31 | -$7.25M | n/m |
| OneMedNet Corp (ONMD) | 2025-12-31 | -$9.60M | n/m |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | -$47.56M | n/m |
| NRC Health (NRC) | 2025-12-31 | $30.21M | -26.7% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $428.47M | -27.3% |
Compare BIAF, ABSI, FOXO, OABI side by side · Screen every company in Services-Commercial Physical & Biological Research ↗